论文部分内容阅读
目的探讨福辛普利联合普伐他汀对慢性心力衰竭(CHF)患者心室重构及血脂代谢的影响。方法选取2013年10月—2016年3月惠州市中医医院收治的CHF患者62例,根据建档顺序分为对照组和观察组,每组31例。在常规治疗基础上,对照组患者采用福辛普利治疗,观察组患者采用福辛普利联合普伐他汀治疗;两组患者均持续治疗3个月。比较两组患者临床疗效,治疗前后心室重构指标[(左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)]、血脂指标[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]及血清炎性因子[肿瘤坏死因子α(TNF-α)、白介素4(IL-4)、白介素6(IL-6)]水平。结果观察组患者临床疗效优于对照组(P<0.05)。两组患者治疗前LVEF、LVESD、LVEDD比较,差异无统计学意义(P>0.05),观察组患者治疗后LVEF高于对照组,LVESD、LVEDD短于对照组(P<0.05)。两组患者治疗前血清TC、TG、LDL-C、HDL-C水平比较,差异无统计学意义(P>0.05);观察组患者治疗后血清TC、TG、LDL-C水平低于对照组(P<0.05),而两组患者治疗后血清HDL-C水平比较,差异无统计学意义(P>0.05)。两组患者治疗前血清TNF-α、IL-4、IL-6水平比较,差异无统计学意义(P>0.05);观察组患者治疗后血清TNF-α、IL-6水平低于对照组,血清IL-4水平高于对照组(P<0.05)。结论普伐他汀联合福辛普利治疗CHF的临床疗效确切,可有效改善患者血脂代谢,减轻炎性反应并抑制心室重构。
Objective To investigate the effects of fosinopril combined with pravastatin on ventricular remodeling and blood lipid metabolism in patients with chronic heart failure (CHF). Methods Sixty-two CHF patients admitted to Huizhou Chinese Medicine Hospital from October 2013 to March 2016 were divided into control group and observation group according to the order of filing, with 31 cases in each group. On the basis of conventional treatment, patients in the control group were treated with fosinopril, and patients in the observation group were treated with fosinopril and pravastatin. Patients in both groups were treated for 3 months. The clinical curative effect, ventricular remodeling index [LVEF, LVESD, LVEDD], blood lipid index [total cholesterol (TC) TG, LDL-C, HDL-C) and serum inflammatory factors [TNF-α, IL-4 IL-4, IL-6] .Results The clinical efficacy of the observation group was better than that of the control group (P <0.05) .There was no significant difference in the LVEF, LVESD and LVEDD between the two groups before treatment > 0.05) .The LVEF in the observation group was higher than that in the control group, LVESD and LVEDD were shorter than those in the control group (P <0.05), the levels of TC, TG, LDL-C and HDL- (P> 0.05). The levels of serum TC, TG and LDL-C in the observation group were lower than those in the control group (P <0.05), but there was no significant difference in the serum HDL-C levels between the two groups (P> 0.05) .There was no significant difference in serum TNF-α, IL-4 and IL-6 levels between the two groups before treatment (P> 0.05) -6 was lower than the control group, serum IL-4 level was higher than the control group (P0.05) .Conclusion Pravastatin combined with fosinopril in the treatment of CHF clinical efficacy is exact, can effectively improve the patient’s blood lipid metabolism, reduce inflammatory response And inhibit ventricular remodeling.